3.1.1 E. coli was the first host in which researchers overexpressed a heterologous protein under a controlled induction, and it has been the workhorse of the industry ever since. The same methods used in 1982 are still sufficient to obtain reasonable yields of many recombinant proteins, but advances in strain engineering technologies have vastly expanded the repertoire of E. coli–based products.
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.
3.2.1 As mentioned above, one of the common features of recombinant expression in E. coli is the tendency for inclusion body production. This can simplify purification because they are easier to separate from the majority of host cell proteins, lipids, and DNA by relatively simple washing and centrifugation, but then processing of inclusion bodies has its own challenges, starting with solubilization. The traditional method for solubilizing inclusion bodies involves chaotropic solvents like urea and guanidine hydrochloride. These agents disrupt the non-covalent interactions within protein aggregates, rendering them soluble. However, their harsh nature often necessitates extensive subsequent refolding steps to regain the protein’s native structure. This process is critical for the recovery of functional proteins but is fraught with challenges due to the potential for protein denaturation and aggregation.
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.
3.3.1 While traditional chaotropic solvents like urea and guanidine hydrochloride are effective for solubilizing inclusion bodies, their harsh nature often complicates subsequent refolding steps. Novel approaches, such as the use of ionic liquids (ILs) and deep eutectic solvents (DESs), offer promising alternatives that can solubilize protein aggregates under milder conditions, preserving native structures and enhancing refolding efficiency. These advancements hold potential for more sustainable and efficient protein production processes in biopharmaceutical applications.[86]
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.
3.4.1 To refold a denatured protein, the denaturant must be removed. Simple dilution of the denaturant can require extremely large volumes at manufacturing scale. Refolding large volumes of solubilized inclusion bodies presents significant challenges, primarily due to the need for careful control of mixing conditions. For instance, a 1,000-L fermenter yielding 8 g/L of inclusion bodies could require up to a 3,200-L vessel for refolding after dilution. This considerable volume must be mixed quickly and thoroughly to prevent protein aggregation and ensure uniform refolding conditions.[86]
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.
3.5.1 Tangential flow filtration (TFF) is a critical step to concentrate protein solutions after the refolding process, making them suitable for further purification. TFF involves passing the refolded protein solution through a membrane that retains the protein while allowing smaller molecules to pass through. This step effectively reduces the processing volume, facilitating more efficient downstream purification steps.
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.
3.6.1 The highly complex nature of biopharmaceuticals places a significant burden on analytical methods and data to support discovery, development, regulatory approval, manufacture, and release. In addition to primary and secondary amino acid sequences and structure, posttranslational modifications — glycosylation, phosphorylation, deamidation, and so on — must all be closely monitored. Product-related impurities, host cell proteins, process impurities, and contaminating species must also be tested and identified. Raw materials must be properly identified; water and air quality must be maintained to rigorous standards; cleanrooms and surfaces must be monitored for contaminations. The stability of intermediate product during processing must be validated, as must the stability of the final product in both its drug substance and drug product forms.
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.
3.7.1 Process analytical technology (PAT) tools are essential for ensuring the quality and consistency of the protein refolding process. These technologies provide real-time monitoring of critical parameters, such as protein concentration, aggregation state, and folding efficiency, allowing for immediate adjustments to process conditions.[2] The real-time data provided by PAT systems enable on-the-fly adjustments, ensuring optimal refolding outcomes. This capability is crucial for maintaining the delicate balance required for successful protein folding, where slight variations in conditions can significantly impact the final product’s quality.[87]
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.